Diane M Richardson1, Elina L Medvedeva1, Christopher B Roberts1, Darren R Linkin2. 1. Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center. 2. Division of Infectious Diseases, Department of Medicine, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania Division of Infectious Diseases, Department of Medicine, Philadelphia Veterans Affairs Medical Center, Pennsylvania.
Abstract
BACKGROUND: Influenza is a significant cause of morbidity and mortality in older adults. High-dose (HD) trivalent inactivated vaccine has increased immunogenicity in older adults compared with standard-dose (SD) vaccine. We assessed the relative effectiveness of HD influenza vaccination (vs SD influenza vaccination). METHODS: We conducted a retrospective cohort study among patients who receive primary care at Veteran Health Administration (VHA) medical centers, and who received influenza vaccine in the 2010-2011 influenza season. The primary outcome was hospitalization for influenza or pneumonia. We also conducted an analysis in subgroups defined by age. RESULTS: We evaluated 25 714 patients who received HD vaccine and 139 511 who received SD vaccine in 23 VHA medical centers. The rate of hospitalization for influenza or pneumonia was 0.3% in both groups in the influenza season. After accounting for patient characteristics in propensity-adjusted analyses, the risk of hospitalization for influenza or pneumonia was not significantly lower among patients receiving HD vaccine vs those receiving SD vaccine (risk ratio, 0.98; 95% confidence interval, .68-1.40). In the subgroup of patients ≥85 years of age, receiving HD (compared with SD) vaccine was associated with lower rates of hospitalization for influenza or pneumonia. CONCLUSIONS: HD vaccine was not found to be more effective than SD vaccine in protecting against hospitalization for influenza or pneumonia; however, we found a protective effect in the oldest subgroup of patients. Additional studies are needed to evaluate the effectiveness of HD vaccine. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Influenza is a significant cause of morbidity and mortality in older adults. High-dose (HD) trivalent inactivated vaccine has increased immunogenicity in older adults compared with standard-dose (SD) vaccine. We assessed the relative effectiveness of HD influenza vaccination (vs SD influenza vaccination). METHODS: We conducted a retrospective cohort study among patients who receive primary care at Veteran Health Administration (VHA) medical centers, and who received influenza vaccine in the 2010-2011 influenza season. The primary outcome was hospitalization for influenza or pneumonia. We also conducted an analysis in subgroups defined by age. RESULTS: We evaluated 25 714 patients who received HD vaccine and 139 511 who received SD vaccine in 23 VHA medical centers. The rate of hospitalization for influenza or pneumonia was 0.3% in both groups in the influenza season. After accounting for patient characteristics in propensity-adjusted analyses, the risk of hospitalization for influenza or pneumonia was not significantly lower among patients receiving HD vaccine vs those receiving SD vaccine (risk ratio, 0.98; 95% confidence interval, .68-1.40). In the subgroup of patients ≥85 years of age, receiving HD (compared with SD) vaccine was associated with lower rates of hospitalization for influenza or pneumonia. CONCLUSIONS:HD vaccine was not found to be more effective than SD vaccine in protecting against hospitalization for influenza or pneumonia; however, we found a protective effect in the oldest subgroup of patients. Additional studies are needed to evaluate the effectiveness of HD vaccine. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Anne M Butler; J Bradley Layton; Vikas R Dharnidharka; John M Sahrmann; Marissa J Seamans; David J Weber; Leah J McGrath Journal: Am J Kidney Dis Date: 2019-08-01 Impact factor: 8.860
Authors: Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers Journal: Vaccine Date: 2016-04-26 Impact factor: 3.641
Authors: Jessica R Cataldi; Laura P Hurley; Megan C Lindley; Sean T O'Leary; Carol Gorman; Michaela Brtnikova; Brenda L Beaty; Lori A Crane; David K Shay; Allison Kempe Journal: J Gen Intern Med Date: 2021-01-22 Impact factor: 6.473
Authors: G K Balasubramani; Won Suk Choi; Mary Patricia Nowalk; Richard K Zimmerman; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Michael L Jackson; Lisa A Jackson; Jessie R Chung; Sarah Spencer; Alicia M Fry; Manish Patel; Brendan Flannery Journal: Vaccine Date: 2020-08-13 Impact factor: 4.169
Authors: Yinong Young-Xu; Julia Thornton Snider; Salaheddin M Mahmud; Ellyn M Russo; Robertus Van Aalst; Edward W Thommes; Jason Kh Lee; Ayman Chit Journal: Euro Surveill Date: 2020-05
Authors: A Gil de Miguel; E Redondo Marguello; J Díez Domingo; R Ortiz de Lejarazu; F Martinón Torres Journal: Rev Esp Quimioter Date: 2020-06-09 Impact factor: 1.553
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan Journal: MMWR Recomm Rep Date: 2018-08-24